Milner welcomes new Head of Target Discovery
We are delighted to welcome Dr Erica Bello as the new Head of Target Discovery at the Milner Therapeutics Institute. Erica brings to the team broad experience in CRISPR screening and advanced disease models, both from her work at the Wellcome Sanger Institute and more...
Milner Institute collaborates to launch Cambridge AI Club for Biomedicine
The AI Club for Biomedicine, launched earlier this month, is a new initiative created to bring together the biomedical AI and machine learning community in Cambridge. This collaboration between the Milner and CRUK Cambridge Institute will be held on the first Thursday...
Milner Institute announces strategic collaboration with NC3Rs
We are delighted to announce a new collaboration with the NC3Rs this month, which has been established to help NC3Rs-funded researchers translate their in vitro models of human disease into industry-relevant genetic assays. The collaboration involves a funding...
Milner affiliate STORM Therapeutics initiate phase I clinical trials
Congratulations to Milner affiliated company STORM Therapeutics, who have announced the start of phase I clinical trials with their first-in-class compound against the RNA modifying enzyme, METTL3. STORM Therapeutics is a clinical stage biotechnology company creating...